Overview

A Study of the Safety and Effectiveness of LY3053102 in Participants With Type 2 Diabetes

Status:
Terminated
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the safety and effectiveness of the study drug known as LY3053102 in participants with Type 2 diabetes mellitus. The study drug will be given in different doses as an injection under the skin. The study is expected to last up to 6 months for each participant. Participants may remain on stable-dose metformin as prescribed by their personal physician.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Exenatide
Metformin